Established Efficacy In Post-Cataract Inflammation and Pain Control

More patients achieved complete resolution of anterior chamber cells with LOTEMAX GEL vs
vehicle at Days 8 and 151-4


LOTEMAX GEL vs vehicle

  • Day 8: 31% (126/409) vs 15% (61/404); P<0.001
  • Day 15: 53% (218/409) vs 26% (105/404); P<0.001

*Pivotal trials: Two, independent, randomized, multicenter, double-masked, parallel-group, vehicle-controlled, pooled studies in 813 patients to examine the safety and efficacy of LOTEMAX GEL in the treatment of postoperative inflammation and pain following cataract surgery.

†Primary efficacy endpoint on Day 8; secondary endpoint on Day 15.

Please see Important Safety Information below.

More patients treated with LOTEMAX GEL were pain free at Days 8 and Day 15 vs vehicle1-4


LOTEMAX GEL vs vehicle

  • Day 8: 75% (304/409) vs 44% (177/404); P<0.001
  • Day 15: 77% (314/409) vs 41% (166/404); P<0.001

*Pivotal trials: Two, independent, randomized, multicenter, double-masked, parallel-group, vehicle-controlled, pooled studies in 813 patients to examine the safety and efficacy of LOTEMAX GEL in the treatment of postoperative inflammation and pain following cataract surgery.


†Primary efficacy endpoint on Day 8; secondary endpoint on Day 15.


Please see Important Safety Information below.

A Tolerability Profile You Expect From Loteprednol Etabonate1

Low incidence of IOP elevations vs vehicle

Risk of significant IOP elevations (≥ 10mm Hg) was similar to that of vehicle: 0.49% (2/409) for LOTEMAX GEL vs 0.25% (1/404) for vehicle If this product is used for 10 days or longer, IOP should be monitored2

Pivotal trials: Two, independent, randomized, multicenter, double-masked, parallel-group, vehicle-controlled, pooled studies in 813 patients to examine the safety and efficacy of LOTEMAX GEL in the treatment of postoperative inflammation and pain following cataract surgery.